Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...
Alumis' Phase 3 ONWARD data show envudeucitinib delivers durable scalp clearance and itch relief through 48 weeks in ...
5don MSN
2 stocks that could soar in Q4
These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth ...
A two-year Japanese real-world study of 66 patients shows the dual IL-17A and IL-17F inhibitor bimekizumab sustained high ...
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its oral psoriasis treatment ICOTYDE (icotrokinra) maintained ...
A national analysis of US ambulatory care visits finds patients with psoriasis have more than eightfold increased odds of ...
Fed up with flakes on your shoulders and an itchy scalp that just won't settle? Before you buy yet another shampoo, here's ...
Zasocitinib demonstrated superiority over deucravacitinib for the treatment of moderate to severe plaque psoriasis, according ...
Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...
Dr. Bunick introduces the panel's second case: a 72-year-old retired school administrator with plaque psoriasis diagnosed at ...
Icotrokinra (Icotyde) sustained PASI 90 in at least 72% of plaque psoriasis patients through two years in Phase III ICONIC-LEAD. Read the full results.
Organizations that have expertise in psoriasis, as well as patient advocacy groups, can provide you with educational resources, offer practical tips for managing your daily tasks, and connect you with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results